BR112023021873A2 - Composição compreendendo um anticorpo ige - Google Patents

Composição compreendendo um anticorpo ige

Info

Publication number
BR112023021873A2
BR112023021873A2 BR112023021873A BR112023021873A BR112023021873A2 BR 112023021873 A2 BR112023021873 A2 BR 112023021873A2 BR 112023021873 A BR112023021873 A BR 112023021873A BR 112023021873 A BR112023021873 A BR 112023021873A BR 112023021873 A2 BR112023021873 A2 BR 112023021873A2
Authority
BR
Brazil
Prior art keywords
composition
ige antibody
ige
antibody
fra
Prior art date
Application number
BR112023021873A
Other languages
English (en)
Portuguese (pt)
Inventor
James Spicer
Sophia Karagiannis
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed by King S College London filed Critical King S College London
Publication of BR112023021873A2 publication Critical patent/BR112023021873A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112023021873A 2021-04-23 2022-04-22 Composição compreendendo um anticorpo ige BR112023021873A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (1)

Publication Number Publication Date
BR112023021873A2 true BR112023021873A2 (pt) 2023-12-19

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021873A BR112023021873A2 (pt) 2021-04-23 2022-04-22 Composição compreendendo um anticorpo ige

Country Status (10)

Country Link
US (1) US20240190955A1 (https=)
EP (1) EP4326770A1 (https=)
JP (1) JP2024514935A (https=)
KR (1) KR20240001136A (https=)
AU (1) AU2022263376A1 (https=)
BR (1) BR112023021873A2 (https=)
CA (1) CA3215850A1 (https=)
MX (1) MX2023012557A (https=)
WO (1) WO2022223784A1 (https=)
ZA (1) ZA202309456B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
EP2764025B1 (en) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antibodies against hmw-maa
US20180333503A1 (en) 2017-05-16 2018-11-22 Immunogen, Inc. Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Also Published As

Publication number Publication date
CA3215850A1 (en) 2022-10-27
US20240190955A1 (en) 2024-06-13
AU2022263376A9 (en) 2023-11-30
AU2022263376A1 (en) 2023-11-23
WO2022223784A1 (en) 2022-10-27
ZA202309456B (en) 2025-03-26
EP4326770A1 (en) 2024-02-28
KR20240001136A (ko) 2024-01-03
MX2023012557A (es) 2023-11-08
JP2024514935A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
CL2020002026A1 (es) Inhibidor de fap.
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
NI201100064A (es) Anticuerpos humanos de la alta afinidad para el receptor il-4 humano fundamento.
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
MX2016003103A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores.
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CL2009000090A1 (es) Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
AR064464A1 (es) Anticuerpos anti - receptor del factor de crecimiento insulinico
CO2021012230A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
BR112019023898A2 (pt) método para tratamento de câncer gástrico, uso de um anticorpo e composição
MX2012011718A (es) Anticuerpos anti-erbb3.
BR112016002199B8 (pt) Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
CL2021002067A1 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
CO2024007192A2 (es) Moléculas de anticuerpo y conjugados
CO2022000481A2 (es) Inhibidores de enzimas
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.
ECSP22056627A (es) Anticuerpos contra la integrina alfa 11 beta 1
BR112023021873A2 (pt) Composição compreendendo um anticorpo ige
BR112022018985A2 (pt) Método para criar anticorpo iga multimérico, e anticorpo iga multimérico multiespecífico
CL2009000177A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas; linea celular de hibridoma que lo produce; composicion farmaceutica que los comprende; ensayo para determinar la presencia de celulas cancerosas; y uso para tratar tumores.